INCY News and Press, Incyte Corporation From 04/25/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

- Phase 3 REACH2 data demonstrate that ruxolitinib (Jakafi ® ) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT) - Results show a significantly greater overall...

Incyte Receives the FDA Approval for Pemazyre Incyte ( INCY ) announced receiving the FDA node for its kinase inhibitor Pemazyre. The drug seeks to treat adults with previously handled, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recept...

The FDA approves Incyte's (NASDAQ: INCY ) Pemazyre (pemigatinib) for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (cancer of the bile ducts) with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test...

  - Pemazyre received Orphan Drug, Breakthrough Therapy and Priority Review designations based on the significant needs of people living with this devastating cancer - - Investor conference call and webcast scheduled for Monday, April 20, 2020, at 8:00 a.m. ET - Incyte (Na...

Incyte ( INCY +4.6% ) initiates a Phase 3 clinical trial, RUXCOVID, evaluating Jakafi (ruxolitinib) plus standard-of-care treatment in COVID-19 patients at least 12 years old who are experiencing cytokine storm , a potentially life-threatening out-of-control immune response. More news...

- Expanded Access Program allowing additional eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib is also open for enrollment in the United States Incyte (Nasdaq:INCY) today announced the initiation of RUXCOVID, a global, randomized, double-blind, placebo-c...

Exelixis (NASDAQ: EXEL) is trading at a bargain price after the market sell-off caused by the COVID-19 pandemic. The biotech stock dropped over 15% from its high of $22.06 in February, now trading around $18. Year to date, the biotechnology stock is up 4.14%, outpacing the Virtus ...

The FDA has signed off on Fast Track status for Yantai, China-based RemeGen 's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE). More news on: GlaxoSmithKline plc, Mallinckrodt plc, Biogen Inc., Healthcare stocks news, Read more ...